Profile
Jeffrey C Bassett, MD MPH Medical Oncology

Jeffrey C Bassett, MD MPH

Medical Oncology, Urologic Oncology
Irvine, CA 92618 (1 other location)
Accepting New Patients Visit Website

About Jeffrey C Bassett, MD MPH

Jeffrey C Bassett, MD MPH is a doctor primarily located in Irvine, CA, with another office in Newport Beach, CA. He has 16 years of experience. His specialties include Medical Oncology, Urologic Oncology. Bassett, MD MPH is affiliated with Hoag Memorial Hospital Presbyterian. He speaks English.

Locations

Jeffrey C Bassett, MD MPH has 2 locations

Hoag Irvine Cancer Center 16105 Sand Canyon Ave Irvine, CA 92618
ACCEPTING NEW PATIENTS
Hoag Urologic Oncology 1525 Superior Ave Ste 210 Newport Beach, CA 92663
ACCEPTING NEW PATIENTS

Specialties

Jeffrey C Bassett, MD MPH has the following 2 SPECIALTIES

Specialty Expertise

Jeffrey C Bassett, MD MPH has the following 7 expertise

  • Bladder Issues
  • Urologic Emergencies
  • Overactive Urinary Bladder
  • Kidney Stones
  • Prostate Cancer
  • Erectile Dysfunction (ED)
  • Prostatitis

Education

16 Years Experience

University of California, Los Angeles

Graduated in 2012

Vanderbilt University Medical Center

Graduated in 2014

UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE

Graduated in 2006

Jeffrey C Bassett, MD MPH Accepts the Following Insurance

  • Aetna PPO
  • Blue Cross
  • Blue Cross Blue Shield
  • HealthNet
  • Motor Vehicle (NJ)
  • UnitedHealthcare

More about Jeffrey C Bassett, MD MPH

Dr. Bassett is one of a small number of cancer surgeons fellowship-trained in Urologic Oncology and Health Services Research. He specializes minimally invasive and advanced surgical options for cancers of the urinary tract including bladder, kidney, prostate, and testicular cancer. Dr. Bassett performs single-incision robotic surgery to optimize his patients’ outcomes with faster recovery. He also offers robotic-assisted salvage prostatectomy for men with persistent cancer after focal/radiation-based treatment. His  research is focused on improving outcomes for urologic cancer patients with the use of genomic testing, 3D imaging/models, and enhanced recovery surgical protocols.